Surrozen (SRZN) Competitors $9.48 +0.08 (+0.85%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$9.42 -0.06 (-0.63%) As of 06/13/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SRZN vs. PVLA, GLUE, TNGX, CRVS, SLDB, IMMP, CYRX, ATXS, TSVT, and AVIRShould you be buying Surrozen stock or one of its competitors? The main competitors of Surrozen include Palvella Therapeutics (PVLA), Monte Rosa Therapeutics (GLUE), Tango Therapeutics (TNGX), Corvus Pharmaceuticals (CRVS), Solid Biosciences (SLDB), Immutep (IMMP), Cryoport (CYRX), Astria Therapeutics (ATXS), 2seventy bio (TSVT), and Atea Pharmaceuticals (AVIR). These companies are all part of the "pharmaceutical products" industry. Surrozen vs. Its Competitors Palvella Therapeutics Monte Rosa Therapeutics Tango Therapeutics Corvus Pharmaceuticals Solid Biosciences Immutep Cryoport Astria Therapeutics 2seventy bio Atea Pharmaceuticals Palvella Therapeutics (NASDAQ:PVLA) and Surrozen (NASDAQ:SRZN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, community ranking, profitability, earnings, analyst recommendations, valuation and risk. Does the media refer more to PVLA or SRZN? In the previous week, Palvella Therapeutics had 10 more articles in the media than Surrozen. MarketBeat recorded 11 mentions for Palvella Therapeutics and 1 mentions for Surrozen. Surrozen's average media sentiment score of 1.89 beat Palvella Therapeutics' score of 1.21 indicating that Surrozen is being referred to more favorably in the news media. Company Overall Sentiment Palvella Therapeutics Positive Surrozen Very Positive Which has more risk & volatility, PVLA or SRZN? Palvella Therapeutics has a beta of -0.1, meaning that its share price is 110% less volatile than the S&P 500. Comparatively, Surrozen has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Which has higher earnings and valuation, PVLA or SRZN? Palvella Therapeutics has higher revenue and earnings than Surrozen. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPalvella Therapeutics$42.81M6.47-$24.54M-$12.10-2.07Surrozen$11.64M6.98-$43.04M-$24.96-0.38 Do insiders and institutionals have more ownership in PVLA or SRZN? 40.1% of Palvella Therapeutics shares are held by institutional investors. Comparatively, 66.6% of Surrozen shares are held by institutional investors. 20.5% of Palvella Therapeutics shares are held by company insiders. Comparatively, 45.2% of Surrozen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community favor PVLA or SRZN? Palvella Therapeutics received 8 more outperform votes than Surrozen when rated by MarketBeat users. Likewise, 100.00% of users gave Palvella Therapeutics an outperform vote while only 31.82% of users gave Surrozen an outperform vote. CompanyUnderperformOutperformPalvella TherapeuticsOutperform Votes15100.00% Underperform VotesNo VotesSurrozenOutperform Votes731.82% Underperform Votes1568.18% Do analysts rate PVLA or SRZN? Palvella Therapeutics presently has a consensus target price of $46.29, indicating a potential upside of 84.77%. Surrozen has a consensus target price of $38.50, indicating a potential upside of 306.12%. Given Surrozen's higher possible upside, analysts clearly believe Surrozen is more favorable than Palvella Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Palvella Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Surrozen 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is PVLA or SRZN more profitable? Palvella Therapeutics' return on equity of -80.93% beat Surrozen's return on equity.Company Net Margins Return on Equity Return on Assets Palvella TherapeuticsN/A -80.93% -59.55% Surrozen N/A -120.51%-54.68% SummaryPalvella Therapeutics beats Surrozen on 10 of the 18 factors compared between the two stocks. Get Surrozen News Delivered to You Automatically Sign up to receive the latest news and ratings for SRZN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SRZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRZN vs. The Competition Export to ExcelMetricSurrozenBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$81.18M$3.09B$5.57B$8.50BDividend YieldN/A1.56%5.28%4.16%P/E Ratio-0.3832.6326.6319.64Price / Sales6.98455.18407.99152.17Price / CashN/A168.6838.2534.64Price / Book0.523.366.964.60Net Income-$43.04M-$72.35M$3.23B$248.06M7 Day Performance11.53%0.30%-1.13%-0.94%1 Month Performance45.85%16.40%8.59%3.52%1 Year Performance-15.28%-15.52%33.63%14.02% Surrozen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRZNSurrozen3.8053 of 5 stars$9.48+0.9%$38.50+306.1%-15.9%$81.18M$11.64M-0.3880Positive NewsPVLAPalvella Therapeutics4.0876 of 5 stars$25.14+4.2%$46.29+84.1%N/A$277.95M$42.81M-2.08N/APositive NewsAnalyst RevisionHigh Trading VolumeGLUEMonte Rosa Therapeutics2.2973 of 5 stars$4.50+7.7%$15.50+244.4%+22.4%$276.80M$159.49M-2.4690TNGXTango Therapeutics2.1255 of 5 stars$2.54+14.4%$12.20+380.3%-44.1%$275.32M$40.99M-2.1590Trending NewsAnalyst RevisionGap DownHigh Trading VolumeCRVSCorvus Pharmaceuticals2.8402 of 5 stars$4.03+6.6%$15.00+272.2%+97.6%$274.72MN/A-4.3330Positive NewsAnalyst RevisionSLDBSolid Biosciences3.8673 of 5 stars$3.54+10.3%$14.90+320.9%-47.0%$274.40M$8.09M-1.16100Analyst RevisionGap UpHigh Trading VolumeIMMPImmutep1.38 of 5 stars$1.86-1.1%$7.00+276.3%-36.3%$271.63M$5.14M0.002,021Analyst DowngradeCYRXCryoport3.4117 of 5 stars$5.40-10.1%$11.00+103.7%-35.5%$270.74M$232.13M-1.601,020Trending NewsInsider TradeGap DownATXSAstria Therapeutics2.3542 of 5 stars$4.78+0.4%$30.00+527.6%-37.6%$269.76MN/A-2.2930News CoverageAnalyst ForecastAnalyst RevisionTSVT2seventy bio1.1954 of 5 stars$5.00flat$4.25-15.0%N/A$266.15M$48.37M-2.69440AVIRAtea Pharmaceuticals3.3506 of 5 stars$3.10+4.4%$6.00+93.5%-14.6%$265.30MN/A-1.5070Positive News Related Companies and Tools Related Companies PVLA Competitors GLUE Competitors TNGX Competitors CRVS Competitors SLDB Competitors IMMP Competitors CYRX Competitors ATXS Competitors TSVT Competitors AVIR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SRZN) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGet in stocks now - and get out on this dateGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Surrozen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Surrozen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SRZN Stock Free SRZN Stock Alerts